Phibro Animal Health Corp(PAHC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 15.77 | EPS (ttm) | 2.43 | Insider Own | 48.48% | Shs Outstand | 21.1M | Perf Week | -1.08% |
| Market Cap | 1.56B | Forward P/E | 9.97 | EPS next Y | 10.07% | Insider Trans | -0.15% | Shs Float | 20.9M | Perf Month | 7.51% |
| Enterprise Value | 2.27B | PEG | 1.18 | EPS next Q | 0.78 | Inst Own | 52.12% | Short Float | 4.94% | Perf Quarter | 3.87% |
| Income | 0.10B | P/S | 1.03 | EPS this Y | 8.6% | Inst Trans | -0.23% | Short Ratio | 4.58 | Perf Half Y | -29.31% |
| Sales | 1.52B | P/B | 4.04 | EPS next 5Y | 8.47% | ROA | 6.97% | Short Interest | 1.03M | Perf YTD | 2.73% |
| Book/sh | 9.5 | P/C | 19.01 | EPS past 3/5Y | 44.61% 12.64% | ROE | 29.72% | 52W High | -36.12% ($60.08) | Perf Year | -7.96% |
| Cash/sh | 2.02 | P/FCF | 157.88 | Sales past 3/5Y | 15.79% 12.74% | ROIC | 8.76% | 52W Low | 35.86% ($28.25) | Perf 3Y | 256.36% |
| Dividend Est. | $0.48 (1.25%) | EV/EBITDA | 8.98 | EPS Y/Y TTM | 106.4% | Gross Margin | 33.61% | Volatility(W/M) | 2.88% 3.54% | Perf 5Y | 74.93% |
| Dividend TTM | 0.48 | EV/Sales | 1.49 | Sales Y/Y TTM | 17.12% | Oper. Margin | 13.23% | ATR (14) | 1.35 | Perf 10Y | 49.05% |
| Dividend Ex-Date | 2026/9/2 | Quick Ratio | 1.27 | EPS Q/Q | 25.12% | Profit Margin | 6.57% | RSI (14) | 54.6 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.96 | Sales Q/Q | 4.77% | SMA20 | 1.21% ($37.92) | Beta | 0.43 | Target Price | $47 |
| Payout | 19.72% | Debt/Eq | 2.05 | Earnings | 2026/8/26 | SMA50 | 4.33% ($36.79) | Rel Volume | 0.53 | Prev Close | $39.03 |
| Employees | 2605 | LT Debt/Eq | 1.95 | EPS/Sales Surpr. | 19.25% 4.07% | SMA200 | -7.04% ($41.29) | Avg Volume(3M) | 0.23M | Price | $38.38 |
| IPO | 2014/4/11 | Option/Short | Yes/Yes | Trades | 2276 | Volume | 118,882 | Change | -1.67% |
🐄 Phibro Animal Health (PAHC) is a global animal health company that develops, manufactures, and sells animal pharmaceuticals and mineral nutritional supplements for livestock and companion animals. The company primarily focuses on products for food-producing animals such as poultry, swine, cattle, and aquaculture, and has diversified its business to include mineral nutrition and industrial specialty chemical products.
Over the past 1 year, roughly in the middle
36% below its 1-year high.
Traded less than usual. That is 53% of its average volume.
PAHC makes money exceptionally well
Of every $100 in sales, $13.23 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +8.6% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $1,577. Peers typically go for $2,112. Compared with its own 5-year average, it is 27% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +74.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 1.25% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 52.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
SAWS AAM Sawgrass US Small Cap Quality Growth ETF 0.02% 
XPH State Street SPDR S&P Pharmaceuticals ETF 0.01% 
PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF 0.01% 
PTH Invesco Dorsey Wright Healthcare Momentum ETF <0.01% 
RZG Invesco S&P SmallCap 600 Pure Growth ETF <0.01% It ranks #29 of 83 in the industry
Based on market cap of $2B.
ALVO#27 Alvotech $2B PER - 
ANIP#28 ANI Pharmaceuticals Inc $2B PER 15.4 PAHC#29 Phibro Animal Health Corp $2B PER 15.8 
ETON#30 Eton Pharmaceuticals Inc $1B PER 135.3 
PCRX#31 Pacira BioSciences Inc $1B PER 104.9 
FAQ
What kind of company is PAHC?
PAHC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of PAHC?
The market cap of PAHC is approximately $1.6B, ranking 2,271 within its sector.
Does PAHC pay dividends?
PAHC has a dividend yield of approximately 1.25%, with an annual dividend of $0.48.
What is the P/E ratio of PAHC?
PAHC has a P/E ratio of approximately 15.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PAHC?
PAHC has recorded a 52-week high of $60.08 and a low of $28.25.
